Paris International Liver Meeting 2027 – Save the Date

Dear Colleagues, We are pleased to invite you to save the date for the Paris International Liver Meeting 2027, taking place January 21–23, 2027, at Maison de la Chimie in Paris, France. Building on the outstanding success of PILM 2026, which attracted 722 participants from 67 countries, we are excited to bring together the international community of hepatology experts once again. PILM 2027 will feature cutting-edge scientific sessions, state-of-the-art lectures, and interactive discussions covering the latest advances in steatotic liver disease (MASLD, MetALD, ALD), viral hepatitis, hepatocellular carcinoma, cholestatic liver diseases, and complications of cirrhosis. Join us to share insights, exchange practical approaches, and advance patient care alongside colleagues from academia, clinical practice, and industry. For more information, visit www.parislivermeeting.com We look forward to seeing you in Paris! Best regards, Laurent Castera and Zobair M. Younossi

Research from Global NASH/MASH Council as Cover Story of Lancet Gastroenterology & Hepatology: Hidden Impact of Alcohol Underreporting on Disease Burden in the US

Research by the Global NASH/MASH Council (GNC), led by Zobair M. Younossi, MD, has been published as the Cover Story of The Lancet Gastroenterology & Hepatology. Using National Health and Nutrition Examination Survey (NHANES) data spanning 1988–2023, the study demonstrates that alcohol consumption is underreported in population surveys, resulting in underestimation of alcohol-related liver disease (ALD) and metabolic dysfunction-associated alcohol-related liver disease (MetALD) burden. When corrected for underreporting, the prevalence of ALD and MetALD nearly doubled compared to uncorrected estimates. The research reveals that ALD carries the highest premature mortality risk among steatotic liver diseases (SLD), with binge drinking identified as the dominant mortality driver in ALD and type 2 diabetes (T2D) as the strongest predictor in metabolic dysfunction-associated steatotic liver disease (MASLD). Notably, the concurrent presence of binge drinking with T2D or hypertension produces synergistic effects associated with particularly hazardous outcomes. These findings underscore the urgent need for systematic screening of alcohol consumption, with particular emphasis on binge drinking, combined with comprehensive assessment of cardiometabolic risk factors. Such integrated approaches are essential to inform targeted clinical interventions and public health strategies aimed at preventing liver disease progression, reducing mortality, and improving patient outcomes. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00376-0/abstract